GlycoEra raises €117.0M Series B round
28 May 2025· Wädenswil, Switzerland· health, biotechnology, protein_degradation, glycoengineering, drug_discovery, autoimmune_diseases
To advance its lead program GE8820 into clinical development, support pipeline expansion across other immunological indications, and initiate first-in-human trials later this year.
Investors
LeadNovo Holdings
Also participating
Sofinnova PartnersLifeArc VenturesQatar Investment AuthorityCatalio Capital ManagementAgent CapitalMP Healthcare Venture ManagementSixty Degree Capital5AM VenturesRoche VenturesBristol Myers Squibb
About GlycoEra
Stage
Series B
Headquarters
Wädenswil, Switzerland
Founded
2020
Team Size
21–50
Sectors
healthbiotechnologyprotein_degradationglycoengineeringdrug_discoveryautoimmune_diseases